Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

The race is on to make the first oral weight loss medicines, but smaller US pharmacies may have already got there – if they ...

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Oral semaglutide (Rybelsus; Novo Nordisk) taken once daily cut the risk of cardiovascular mortality, nonfatal MI, or nonfatal stroke in the trial by 14% after a mean follow-up of 47.5 months, a ...

Patients who received preoperative semaglutide had lower postoperative total weight loss at 12 months compared with controls. Median HbA1c levels and diabetes remission at 1 year were similar ...

The trial was sponsored by Novo Nordisk, the pharmaceutical company that manufactures semaglutide under brand names like Ozempic and Rybelsus. While the results are promising, researchers note ...

Semaglutide is a drug that the FDA has approved for appetite suppression and weight loss under the brand name Wegovy. Semaglutide is also currently available in both oral tablet and injectable ...

Semaglutide medications like Ozempic and Wegovy have exploded in popularity in recent years due to their effectiveness in diabetes control and weight loss. Research has revealed additional ...

Studies show promising results for semaglutide as a potential treatment ... responsibly when drinking in public — never driving under the influence. (Bless those ride-share apps.) ...